Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125967311 | 12596731 | 1 | I | 20121026 | 20160718 | 20160726 | 20160726 | EXP | FR-ASTRAZENECA-2016SE79732 | ASTRAZENECA | 63.00 | YR | M | Y | 0.00000 | 20160726 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125967311 | 12596731 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | 36530 | UG | Y | U | 21773 | 10 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | |||
| 125967311 | 12596731 | 2 | SS | JANUMET | METFORMIN HYDROCHLORIDESITAGLIPTIN PHOSPHATE | 1 | Oral | 50MG/1000MG TWICE A DAY | 0 | ||||||||||
| 125967311 | 12596731 | 3 | C | NOVONORM | REPAGLINIDE | 1 | Oral | 0 | 4 | MG | TID | ||||||||
| 125967311 | 12596731 | 4 | C | GLUCOPHAGE | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 1000 | MG | TID | ||||||||
| 125967311 | 12596731 | 5 | C | AMAREL | GLIMEPIRIDE | 1 | Oral | 0 | 3 | MG | QD | ||||||||
| 125967311 | 12596731 | 6 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 0 | |||||||||||
| 125967311 | 12596731 | 7 | C | ZYLORIC | ALLOPURINOL | 1 | Oral | 0 | 300 | MG | QD | ||||||||
| 125967311 | 12596731 | 8 | C | LEVOTHYROX | LEVOTHYROXINE | 1 | Oral | 0 | 1 | DF | QD | ||||||||
| 125967311 | 12596731 | 9 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 0 | 75 | MG | QD | ||||||||
| 125967311 | 12596731 | 10 | C | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 125967311 | 12596731 | 11 | C | COOLMETEC | HYDROCHLOROTHIAZIDEOLMESARTAN MEDOXOMIL | 1 | Oral | 3 MG, DAILY, 20MG/12.5MG A DAY | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125967311 | 12596731 | 1 | Type 2 diabetes mellitus |
| 125967311 | 12596731 | 2 | Type 2 diabetes mellitus |
| 125967311 | 12596731 | 3 | Type 2 diabetes mellitus |
| 125967311 | 12596731 | 4 | Type 2 diabetes mellitus |
| 125967311 | 12596731 | 5 | Type 2 diabetes mellitus |
| 125967311 | 12596731 | 6 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125967311 | 12596731 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125967311 | 12596731 | Adenocarcinoma pancreas | |
| 125967311 | 12596731 | Glycosylated haemoglobin increased | |
| 125967311 | 12596731 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125967311 | 12596731 | 1 | 20110325 | 20160404 | 0 | |
| 125967311 | 12596731 | 2 | 2010 | 20110325 | 0 | |
| 125967311 | 12596731 | 3 | 20110325 | 0 | ||
| 125967311 | 12596731 | 4 | 20110325 | 0 | ||
| 125967311 | 12596731 | 5 | 20110325 | 0 | ||
| 125967311 | 12596731 | 6 | 20121026 | 0 |